The potential of GLP-1 agonists in weight loss has been a topic of ongoing discussion, but FDA approval for obesity has only been granted in the past decade
In the SURMOUNT5 trial, participants lost an average of 20.2 % of their baseline body weight over 72 weeks with tirzepatide, with a greater proportion achieving weight-loss thresholds of 1525 % compared with semaglutide
Read More Is Online GLP-1 Weight Loss Right For You
What Theyre FDA-Approved For Currently, GLP-1 medications are approved for: Type 2 diabetes Obesity and weight management Reducing cardiovascular risk in people with heart or kidney disease MASH (metabolic-associated steatohepatitis) , formerly called NASH, a type of fatty liver disease Microdosing: What It Means Microdosing usually refers to staying at a very low dosesay, 0.25 mg of semaglutidelong-term, rather than gradually increasing to the therapeutic dose
(2023) 7:bvad056
The goal is not to eat more, it is to eat adequately and intentionally to support healing and metabolic stability
